Download PDF
CC BY 4.0 · Journal of Child Science 2021; 11(01): e133-e140
DOI: 10.1055/s-0041-1731077
Review Article

Current Treatment Guidelines of SARS-CoV-2 Related Multisystem Inflammatory Syndrome in Children: A Literature Review and Expert Opinion

Alireza Ghodsi 
1   Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
,
Mehrdad Sarabi
1   Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
,
Abdolreza Malek
2   Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
,
Ali Khakshour
2   Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a systemic disorder that seems to be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since April 2020, there have been multiple reports about children with this new condition worldwide, including Europe, Asia, Latin America, and North America. The symptoms of this syndrome mimic the clinical manifestations of Kawasaki disease; therefore, the treatment of Kawasaki disease, as well as supportive care, was the management of choice in children with MIS-C in the early days of recognizing it. It is important to precisely ascertain the risk of COVID-19 infection and its severity in children and to acknowledge the management of this syndrome, with reliable data from cohorts, trials, and experts' opinions. In the current review, we summarize the current management guidelines for MIS-C and present our own protocol to answer some clinical questions regarding MIS-C management during the COVID-19 pandemic.

Keywords

COVID-19 - SARS-CoV-2 - multisystem inflammatory syndrome in children - treatment - guideline


Publication History

Received: 04 February 2021

Accepted: 09 April 2021

Article published online:
22 June 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Ghodsi A, Azarfar A, Ghahremani S. A review of coronavirus disease (COVID-19) in children. J Pediatr Neurol 2020;8(03):
    PubMedGoogle Scholar
  • 2 Farhat AS, Sayedi SJ, Akhlaghi F, Hamedi A, Ghodsi A. Coronavirus (COVID-19) infection in newborns. Int J Pediatr 2020; 8 (06) 11513-11517
    PubMedGoogle Scholar
  • 3 Zhu N, Zhang D, Wang W. et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 (08) 727-733
    CrossrefPubMedGoogle Scholar
  • 4 Gorbalenya AE, Baker SC, Baric R. et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses–a statement of the Coronavirus Study Group. BioRxiv 2020
    PubMedGoogle Scholar
  • 5 Hedrich CM, Schnabel A, Hospach T. Kawasaki disease. Front Pediatr 2018; 6: 198
    CrossrefPubMedGoogle Scholar
  • 6 Turnier JL, Anderson MS, Heizer HR, Jone P-N, Glodé MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics 2015; 136 (03) e609-e614
    CrossrefPubMedGoogle Scholar
  • 7 Catalano-Pons C, Quartier P, Leruez-Ville M. et al. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants. Clin Infect Dis 2005; 41 (05) e53-e56
    CrossrefPubMedGoogle Scholar
  • 8 Whittaker E, Bamford A, Kenny J. et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324 (03) 259-269
    CrossrefPubMedGoogle Scholar
  • 9 Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel) 2020; 7 (07) 69
    PubMedGoogle Scholar
  • 10 Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19: The Royal College of Paediatrics and Child Health. Accessed 2020 at: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims
    PubMedGoogle Scholar
  • 11 World Health Organization Scientif Brief. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Accessed 2020 at: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
    PubMedGoogle Scholar
  • 12 Health Alert Network (HAN). Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Accessed 2019 at: https://emergency.cdc.gov/han/2020/han00432.asp
    PubMedGoogle Scholar
  • 13 McCrindle BW, Rowley AH, Newburger JW. et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017; 135 (17) e927-e999
    CrossrefPubMedGoogle Scholar
  • 14 Newburger JW, Takahashi M, Gerber MA. et al; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110 (17) 2747-2771
    CrossrefPubMedGoogle Scholar
  • 15 Verdoni L, Mazza A, Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395 (10239): 1771-1778
    CrossrefPubMedGoogle Scholar
  • 16 Toubiana J, Poirault C, Corsia A. et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020; 369: m2094
    CrossrefPubMedGoogle Scholar
  • 17 Cheung EW, Zachariah P, Gorelik M. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 2020; 324 (03) 294-296
    CrossrefPubMedGoogle Scholar
  • 18 Belhadjer Z, Méot M, Bajolle F. et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020
    PubMedGoogle Scholar
  • 19 Kanegaye JT, Wilder MS, Molkara D. et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123 (05) e783-e789
    CrossrefPubMedGoogle Scholar
  • 20 Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 2005; 191 (04) 492-498
    CrossrefPubMedGoogle Scholar
  • 21 Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191 (04) 499-502
    CrossrefPubMedGoogle Scholar
  • 22 Ghodsi A, Malek A, Ghahremani S. A review of multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Hormozgan Medical J 2020;24(04):
    PubMedGoogle Scholar
  • 23 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med 2020; 383 (04) 334-346
    CrossrefPubMedGoogle Scholar
  • 24 Zou H, Lu J, Liu J. et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis 2021; 102: 319-326
    CrossrefPubMedGoogle Scholar
  • 25 Shulman S. Pediatric COVID-associated multi-system inflammatory syndrome (PMIS). J Pediat Inf Disc Soc 2020; DOI: 10.1093/jpids/piaa061.
    CrossrefPubMedGoogle Scholar
  • 26 Ghodsi A, Mahmoudabadi E, Ghahremani S, Malek A. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection. Arch Pediatr Infect Dis 2021; DOI: 10.5812/pedinfect.109915.
    CrossrefPubMedGoogle Scholar
  • 27 Grimaud M, Starck J, Levy M. et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care 2020; 10 (01) 69
    CrossrefPubMedGoogle Scholar
  • 28 Venturini E, Montagnani C, Garazzino S. et al; Italian SITIP-SIP SARS-Cov-2 pediatric infection study group. Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. Ital J Pediatr 2020; 46 (01) 139
    CrossrefPubMedGoogle Scholar
  • 29 Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). Accessed 2020 at: https://www.cdc.gov/mis-c/hcp/
    PubMedGoogle Scholar
  • 30 American academy of pediatrics. Accessed 2019 at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/
    PubMedGoogle Scholar
  • 31 Ziaee V, Assari R, Mamishi S. et al. An algorithmic approach to multisystem inflammatory syndrome in children with COVID-19: Tehran Children's Medical Center Protocol. Iran J Pediatr 2020;30(05):
    PubMedGoogle Scholar
  • 32 children's hospital of philadelphia guideline. Accessed 2020 at: https://www.chop.edu/clinical-pathway/multisystem-inflammatory-syndrome-mis-c-clinical-pathway
    PubMedGoogle Scholar
  • 33 Alhazzani W, Møller MH, Arabi YM. et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020; 46 (05) 854-887
    CrossrefPubMedGoogle Scholar
  • 34 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395 (10237): 1607-1608
    CrossrefPubMedGoogle Scholar
  • 35 Chiotos K, Bassiri H, Behrens EM. et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc 2020
    PubMedGoogle Scholar
  • 36 Deza Leon MP, Redzepi A, McGrath E. et al. COVID-19–associated pediatric multisystem inflammatory syndrome. J Pediatric Infect Dis Soc 2020; 9 (03) 407-408
    CrossrefPubMedGoogle Scholar
  • 37 Hennon TR, Penque MD, Abdul-Aziz R. et al. COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol 2020; 101232
    CrossrefPubMedGoogle Scholar
  • 38 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol 2020; 72 (11) 1791-1805
    CrossrefPubMedGoogle Scholar
  • 39 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. version 2. Arthritis Rheumatol 2020; DOI: 10.1002/art.41616.
    CrossrefPubMedGoogle Scholar
  • 40 Capone CA, Subramony A, Sweberg T. et al; Northwell Health COVID-19 Research Consortium. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection. J Pediatr 2020; 224: 141-145
    CrossrefPubMedGoogle Scholar
  • 41 Ouldali N, Toubiana J, Antona D. et al; French Covid-19 Paediatric Inflammation Consortium. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 2021; 325 (09) 855-864
    CrossrefPubMedGoogle Scholar
  • 42 Jiang L, Tang K, Levin M. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20 (11) e276-e288
    CrossrefPubMedGoogle Scholar
  • 43 Chiotos K, Hayes M, Kimberlin DW. et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc 2020
    PubMedGoogle Scholar
  • 44 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med 2020
    PubMedGoogle Scholar
  • 45 Loke Y-H, Berul CI, Harahsheh AS. Multisystem inflammatory syndrome in children: is there a linkage to Kawasaki disease?. Trends Cardiovasc Med 2020; 30 (07) 389-396
    CrossrefPubMedGoogle Scholar
  • 46 Zhao J-Y, Yan J-Y, Qu J-M. Interpretations of “diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)”. Chin Med J (Engl) 2020; 133 (11) 1347-1349
    CrossrefPubMedGoogle Scholar
  • 47 Kobayashi T, Saji T, Otani T. et al; RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379 (9826): 1613-1620
    CrossrefPubMedGoogle Scholar
  • 48 Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2017; 1 (01) CD011188
    PubMedGoogle Scholar
  • 49 Horby P, Landrain M. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Nuffield Dept Population Health; Accessed 2020 at: https://www.remapcap.org/covid19publications/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
    Google Scholar
  • 50 Horby P, Mafham M, Linsell L. et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. MedRxiv 2020
    PubMedGoogle Scholar
  • 51 Hadjadj J, Yatim N, Barnabei L. et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. MedRxiv 2020
    PubMedGoogle Scholar
  • 52 Trouillet-Assant S, Viel S, Gaymard A. et al; COVID HCL Study group. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol 2020; 146 (01) 206-208.e2
    CrossrefPubMedGoogle Scholar